FTXH Holdings
51 holdings in the fund's latest file; the data source updated it on Oct 8, 2026.
Top 25 Holdings
| # | Holding | Weight | Shares (as reported) | Value (as reported) |
|---|
| 1 | AbbVie Inc. | 7.71% | 298,850 | $81.1M |
| 2 | Eli Lilly and Company | 7.49% | 66,248 | $78.8M |
| 3 | Pfizer Inc. | 7.17% | 2,692,595 | $75.4M |
| 4 | Johnson & Johnson | 7.08% | 288,252 | $74.5M |
| 5 | Merck & Co., Inc. | 7.04% | 518,620 | $74.1M |
| 6 | Viatris Inc. | 3.86% | 2,320,754 | $40.6M |
| 7 | Biogen Inc. | 3.74% | 176,856 | $39.3M |
| 8 | Gilead Sciences, Inc. | 3.66% | 261,826 | $38.4M |
| 9 | Amgen Inc. | 3.50% | 89,130 | $36.8M |
| 10 | United Therapeutics Corporation | 3.45% | 66,644 | $36.3M |
| 11 | Regeneron Pharmaceuticals, Inc. | 3.38% | 47,950 | $35.6M |
| 12 | Vertex Pharmaceuticals Incorporated | 3.38% | 70,365 | $35.6M |
| 13 | Zoetis Inc. | 3.38% | 496,960 | $35.6M |
| 14 | Incyte Corporation | 3.32% | 307,484 | $34.9M |
| 15 | Bristol-Myers Squibb Company | 3.25% | 573,501 | $34.2M |
| 16 | Jazz Pharmaceuticals Plc | 2.68% | 121,813 | $28.2M |
| 17 | Exelixis, Inc. | 2.37% | 426,811 | $24.9M |
| 18 | Illumina, Inc. | 2.25% | 88,493 | $23.7M |
| 19 | Halozyme Therapeutics, Inc. | 1.62% | 153,827 | $17.0M |
| 20 | Medpace Holdings, Inc. | 1.52% | 26,398 | $16.0M |
| 21 | Neurocrine Biosciences, Inc. | 1.23% | 90,532 | $13.0M |
| 22 | BioMarin Pharmaceutical Inc. | 1.18% | 224,384 | $12.4M |
| 23 | Alnylam Pharmaceuticals, Inc. | 1.17% | 54,883 | $12.3M |
| 24 | Elanco Animal Health Incorporated | 1.17% | 549,621 | $12.3M |
| 25 | Charles River Laboratories International, Inc. | 1.06% | 37,068 | $11.1M |
Sector Weights
Country Weights
- United States: 96.31%
- Ireland: 3.12%
- United Kingdom: 0.51%
- Other: 0.06%
Shares, value and weight are as reported in the file, dated by the data source's last update of it (not the date of the positions), never adjusted; a split warning appears only for a split close to or after that date, and its absence does not mean the count is on today's share basis. Weights as the fund reports them. Leveraged and inverse funds list swaps and cash, so weights can be negative or add up past 100.